These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 8449968)
21. Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors. Howell RW; Rao DV; Sastry KS Med Phys; 1989; 16(1):66-74. PubMed ID: 2921982 [TBL] [Abstract][Full Text] [Related]
22. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Srivastava SC Cancer Biother Radiopharm; 1996 Feb; 11(1):43-50. PubMed ID: 10851519 [TBL] [Abstract][Full Text] [Related]
23. Magnetically enhanced protection of bone marrow from beta particles emitted by bone-seeking radionuclides: theory of application. Raylman RR; Wahl RL Med Phys; 1995 Aug; 22(8):1285-92. PubMed ID: 7476715 [TBL] [Abstract][Full Text] [Related]
24. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. Goddu SM; Rao DV; Howell RW J Nucl Med; 1994 Mar; 35(3):521-30. PubMed ID: 8113908 [TBL] [Abstract][Full Text] [Related]
25. [Boron neutron capture a a new radiotherapy model]. Hideghéty K; Sauerwwein W; Rassuw J; Sack H Orv Hetil; 1998 Mar; 139(12):675-9. PubMed ID: 9555163 [TBL] [Abstract][Full Text] [Related]
26. Tumor imaging and therapy. Scott AM; Larson SM Radiol Clin North Am; 1993 Jul; 31(4):859-79. PubMed ID: 8337372 [TBL] [Abstract][Full Text] [Related]
33. Comparison of different classes of radionuclides for potential use in radioimmunotherapy. Karagiannis TC Hell J Nucl Med; 2007; 10(2):82-8. PubMed ID: 17684582 [TBL] [Abstract][Full Text] [Related]
34. Innovation, Impact, and Strategic Importance of Alpha-Emitting Radionuclides. Mirzadeh S J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S21-S25. PubMed ID: 31420270 [TBL] [Abstract][Full Text] [Related]
35. Rational evaluation of the therapeutic effect and dosimetry of auger electrons for radionuclide therapy in a cell culture model. Shinohara A; Hanaoka H; Sakashita T; Sato T; Yamaguchi A; Ishioka NS; Tsushima Y Ann Nucl Med; 2018 Feb; 32(2):114-122. PubMed ID: 29238922 [TBL] [Abstract][Full Text] [Related]
36. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. Govindan SV; Goldenberg DM; Elsamra SE; Griffiths GL; Ong GL; Brechbiel MW; Burton J; Sgouros G; Mattes MJ J Nucl Med; 2000 Dec; 41(12):2089-97. PubMed ID: 11138697 [TBL] [Abstract][Full Text] [Related]
37. Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production. Uusijärvi H; Bernhardt P; Rösch F; Maecke HR; Forssell-Aronsson E J Nucl Med; 2006 May; 47(5):807-14. PubMed ID: 16644751 [TBL] [Abstract][Full Text] [Related]
38. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. Boyd M; Ross SC; Dorrens J; Fullerton NE; Tan KW; Zalutsky MR; Mairs RJ J Nucl Med; 2006 Jun; 47(6):1007-15. PubMed ID: 16741311 [TBL] [Abstract][Full Text] [Related]
39. Cancer therapy with alpha-emitters labeled peptides. Dadachova E Semin Nucl Med; 2010 May; 40(3):204-8. PubMed ID: 20350629 [TBL] [Abstract][Full Text] [Related]